DermatologyNews.net

Dermatology Xagena

Search results for "Metastatic melanoma"

Preliminary data from a pivotal phase 2 clinical trial of PLX4032 ( RG7204, Vemurafenib, Zelboraf ) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients, are present ...


The BRAF inhibitor Vemurafenib ( Zelboraf ) represents a new standard of care for metastatic melanoma patients with BRAF V600 mutations after showing improved progression free and overall survival in ...


Researchers from UCLA's Jonsson Comprehensive Cancer Center reported that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melan ...


Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlativ ...


A phase III study of the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), compared to single agent therapy with Dabrafenib in patients with BRAF V600 E or K mutation positive unrese ...


Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv ...


In the BRIM-3 trial, Vemurafenib ( Zelboraf ) was associated with risk reduction versus Dacarbazine ( Deticene ) of both death and progression in patients with advanced BRAFV600 mutation-positive mela ...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with ...


Keytruda ( Pembrolizumab ) is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Pembrolizumab blocks the interactio ...